Celgene tech scores again with new option in ultrarare cancer

24 November 2021
aadi_big

mTOR pathway specialist Aadi Bioscience (Nasdaq: AADI) has secured US approval for its intravenously-administered oncology therapy Fyarro (sirolimus).

The decision makes Aadi, a Californian precision medicine company, the first to address a very rare and aggressive type of sarcoma, perivascular epithelioid cell tumor (PEComa).

The company reportedly plans to launch at the start of 2022 with a list price of around $39,000 per month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology